Global Viral Vector and Plasmid DNA Industry Outlook 2022: Overview, Opportunities, Key Companies and Forecast to 2028
Executive Summary
According to GRD Survey data, the global Viral Vector and Plasmid DNA market is estimated at 670 million US$ in 2021 and is expected to 2670 million US$ by the end of 2028, growing at a CAGR of 21.9% in the forecast period from 2022 to 2028.
This report studies the Viral Vector and Plasmid DNA market dynamics from angles such as new entries, mergers and acquisitions, fundings, exit and major technology breakthroughs. Market performance is evaluated through market size (Million USD) by players, regions, product types and end industries. This report also studies the global market competition landscape, market drivers and trends, opportunities and challenges, risks and entry barriers, sales channels, distributors and Porter's Five Forces Analysis.
Geographically, this report is segmented into several key regions, with revenue, market share and growth Rate of Viral Vector and Plasmid DNA in these regions, from 2016 to 2027, covering
North America (United States, Canada and Mexico)
Europe (Germany, France, UK, Italy, Spain and Russia, etc.)
Asia-Pacific (China, Japan, Korea, Southeast Asia, India, Australia)
South America (Brazil, Argentina, Colombia, etc.)
Middle East and Africa (Turkey, Saudi Arabia, South Africa, etc.)
Market Snapshot, By Product Type
Plasmid DNA
Viral Vector
Market Snapshot, By Application
Cancer
Virus Infection
Hereditary Disease
Main Market Players Analyzed in this report, including:
Yposkesi
VGXI
UniQure
Richter-Helm
PlasmidFactory
Oxford BioMedica
OBiO Technology
MolMed
MassBiologics
Lonza
Jikai Gene
Gene Synthesis
FUJIFILM Diosynth Biotechnologies
FinVector
Eurogentec
Cobra Biologics
Cell and Gene Therapy Catapult
Brammer Bio
Biovian
BioReliance
Aldevron
The study objectives of this report are:
To study and analyze the global Viral Vector and Plasmid DNA market size (Million USD) by company, key regions/countries, products and application, history data from 2016 to 2020, and forecast to 2027.
To understand industry structure of Viral Vector and Plasmid DNA market by identifying its various subsegments.
To share detailed information about the key factors influencing the growth of the market (growth potential, opportunities, drivers, industry-specific challenges and risks).
To identify the key global Viral Vector and Plasmid DNA manufacturers and regional typical players, to define, describe and analyze their sales volume, value, market share, market competition landscape, SWOT analysis and development plans in next few years.
To analyze the Viral Vector and Plasmid DNA market with respect to individual growth trends, future prospects, and their contribution to the total market.
To project the value and volume of Viral Vector and Plasmid DNA submarkets, with respect to key regions (along with their respective key countries).
To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.
To strategically profile the key players and comprehensively analyze their growth strategies.
In this study, the years considered to estimate the market size of Viral Vector and Plasmid DNA are as follows:
History Year: 2016-2020
Base Year: 2020
Estimated Year: 2021
Forecast Year 2021 to 2027
This report includes the estimation of market size from top-down approach by analyzing major submarkets and their major driving factors, and verified from bottom-up approaches. Key players in the market have been identified through secondary research, and their market shares have been determined through primary and secondary research. All percentage shares, splits, and breakdowns have been determined using secondary sources and verified from primary sources.
For the data information by region, company, type and application, 2020 is considered as the base year. Whenever data information was unavailable for the base year, the prior year has been considered.
Key Stakeholders Considered in the study:
Raw material vendors
Distributors/traders/wholesalers/suppliers
Regulatory authorities, including government agencies and NGO
Commercial research & development (R&D) institutions
Importers and exporters
Government organizations, research organizations, and consulting firms
Trade/Industrial associations
End-use industries
Table of Content
Table of Contents
1 Market Definition & Scope
1.1 Definition & Scope
1.2 Viral Vector and Plasmid DNA Product Specifications
1.3 Main Events (Entry, M&A, Exit, Technology and Capital Activity)
1.4 Global Viral Vector and Plasmid DNA Market Performance and Outlook
2 Market Development Performance under COVID-19
2.1 Influencing Factors of Industry Development in the Next Five Years
2.1.1 Drivers
2.1.2 Restraints
2.1.3 Opportunities
2.2 Porter’s Five Forces Analysis
2.3 Comparison of Alternatives and Viral Vector and Plasmid DNA
3 3 Industrial Lift Cycle and Main Buyers Analysis
3.1 Industry Life Cycle Analysis
3.2 Key Buying Industries/Consumers
3.2.1 Major Buyers in Cancer
3.2.2 Major Buyers in Virus Infection
4 Market Segment: by Type
4.1 Viral Vector and Plasmid DNA Type Introduction
4.1.1 Plasmid DNA
4.1.2 Viral Vector
4.2 Global Viral Vector and Plasmid DNA Revenue by Type 2016-2021
5 Market Segment: by Application
5.1 Viral Vector and Plasmid DNA Type Introduction
5.1.1 Cancer
5.1.2 Virus Infection
5.1.3 Hereditary Disease
5.2 Global Viral Vector and Plasmid DNA Revenue by Application 2016-2021
6 Marke Segment: by Region
6.1 Global Viral Vector and Plasmid DNA Market by Region
6.2 North America Viral Vector and Plasmid DNA Market 2016-2021
6.3 Europe Viral Vector and Plasmid DNA Market 2016-2021
6.4 Asia Pacific Viral Vector and Plasmid DNA Market 2016-2021
6.5 South America Viral Vector and Plasmid DNA Market 2016-2021
6.6 Middle East and Africa Viral Vector and Plasmid DNA Market 2016-2021
7 North America
7.1 North America Viral Vector and Plasmid DNA Market by Country 2016-2021
7.2 United States
7.3 Canada
7.4 Mexico
8 Europe
8.1 Europe Viral Vector and Plasmid DNA Market by Country 2016-2021
8.2 Germany
8.3 France
8.4 UK
8.5 Italy
8.6 Russia
8.7 Spain
9 Asia Pacific
9.1 Asia Pacific Viral Vector and Plasmid DNA Market by Country 2016-2021
9.2 China
9.3 Japan
9.4 Korea
9.5 Southeast Asia
9.6 India
9.7 Australia
10 South America
10.1 South America Viral Vector and Plasmid DNA Market by Country 2016-2021
10.2 Brazil
10.3 Argentina
10.4 Colombia
11 Middle East and Africa
11.1 Middle East and Africa Viral Vector and Plasmid DNA Market by Country 2016-2021
11.2 Turkey
11.3 Saudi Arabia
11.4 South Africa
12 Key Participants Company Information
12.1 Yposkesi
12.1.1 Yposkesi Company Information
12.1.2 Yposkesi Viral Vector and Plasmid DNA Product Portfolio, Specification and Application
12.1.3 Yposkesi Viral Vector and Plasmid DNA Revenue and Gross Margin (2019-2021)
12.1.4 Yposkesi Key Development
12.2 VGXI
12.2.1 VGXI Company Information
12.2.2 VGXI Viral Vector and Plasmid DNA Product Portfolio, Specification and Application
12.2.3 VGXI Viral Vector and Plasmid DNA Revenue and Gross Margin (2019-2021)
12.2.4 VGXI Key Development
12.3 UniQure
12.3.1 UniQure Company Information
12.3.2 UniQure Viral Vector and Plasmid DNA Product Portfolio, Specification and Application
12.3.3 UniQure Viral Vector and Plasmid DNA Revenue and Gross Margin (2019-2021)
12.3.4 UniQure Key Development
12.4 Richter-Helm
12.4.1 Richter-Helm Company Information
12.4.2 Richter-Helm Viral Vector and Plasmid DNA Product Portfolio, Specification and Application
12.4.3 Richter-Helm Viral Vector and Plasmid DNA Revenue and Gross Margin (2019-2021)
12.4.4 Richter-Helm Key Development
12.5 PlasmidFactory
12.5.1 PlasmidFactory Company Information
12.5.2 PlasmidFactory Viral Vector and Plasmid DNA Product Portfolio, Specification and Application
12.5.3 PlasmidFactory Viral Vector and Plasmid DNA Revenue and Gross Margin (2019-2021)
12.5.4 PlasmidFactory Key Development
12.6 Oxford BioMedica
12.6.1 Oxford BioMedica Company Information
12.6.2 Oxford BioMedica Viral Vector and Plasmid DNA Product Portfolio, Specification and Application
12.6.3 Oxford BioMedica Viral Vector and Plasmid DNA Revenue and Gross Margin (2019-2021)
12.6.4 Oxford BioMedica Key Development
12.7 OBiO Technology
12.7.1 OBiO Technology Company Information
12.7.2 OBiO Technology Viral Vector and Plasmid DNA Product Portfolio, Specification and Application
12.7.3 OBiO Technology Viral Vector and Plasmid DNA Revenue and Gross Margin (2019-2021)
12.7.4 Oxford BioMedica Key Development
12.9 MassBiologics
12.9.1 MassBiologics Company Information
12.9.2 MassBiologics Viral Vector and Plasmid DNA Product Portfolio, Specification and Application
12.9.3 MassBiologics Viral Vector and Plasmid DNA Revenue and Gross Margin (2019-2021)
12.9.4 MassBiologics Key Development
12.8 MolMed
12.8.1 MolMed Company Information
12.8.2 MolMed Viral Vector and Plasmid DNA Product Portfolio, Specification and Application
12.8.3 MolMed Viral Vector and Plasmid DNA Revenue and Gross Margin (2019-2021)
12.8.4 MolMed Key Development
12.11 Jikai Gene
12.11.1 Jikai Gene Company Information
12.11.2 Jikai Gene Viral Vector and Plasmid DNA Product Portfolio, Specification and Application
12.11.3 Jikai Gene Viral Vector and Plasmid DNA Revenue and Gross Margin (2019-2021)
12.11.4 Jikai Gene Key Development
12.12 Gene Synthesis
12.12.1 Gene Synthesis Company Information
12.12.2 Gene Synthesis Viral Vector and Plasmid DNA Product Portfolio, Specification and Application
12.12.3 Gene Synthesis Viral Vector and Plasmid DNA Revenue and Gross Margin (2019-2021)
12.12.4 Gene Synthesis Key Development
12.13 FUJIFILM Diosynth Biotechnologies
12.13.1 FUJIFILM Diosynth Biotechnologies Company Information
12.13.2 FUJIFILM Diosynth Biotechnologies Viral Vector and Plasmid DNA Product Portfolio, Specification and Application
12.13.3 FUJIFILM Diosynth Biotechnologies Viral Vector and Plasmid DNA Revenue and Gross Margin (2019-2021)
12.13.4 FUJIFILM Diosynth Biotechnologies Key Development
12.14 FinVector
12.14.1 FinVector Company Information
12.14.2 FinVector Viral Vector and Plasmid DNA Product Portfolio, Specification and Application
12.14.3 FinVector Viral Vector and Plasmid DNA Revenue and Gross Margin (2019-2021)
12.14.4 FinVector Key Development
12.15 Eurogentec
12.15.1 Eurogentec Company Information
12.15.2 Eurogentec Viral Vector and Plasmid DNA Product Portfolio, Specification and Application
12.15.3 Eurogentec Viral Vector and Plasmid DNA Revenue and Gross Margin (2019-2021)
12.15.4 Eurogentec Key Development
12.17 Cell and Gene Therapy Catapult
12.18 Brammer Bio
12.19 Biovian
12.20 BioReliance
12.21 Aldevron
13 Global Viral Vector and Plasmid DNA Market Forecast by Region by Type and by Application
13.1 Global Viral Vector and Plasmid DNA Revenue Forecast 2022-2027
13.2 Global Viral Vector and Plasmid DNA Forecast by Regions
13.3 Global Viral Vector and Plasmid DNA Forecast by Type
13.4 Global Viral Vector and Plasmid DNA Forecast by Application
14 Analyst Views and Conclusions
15 Methodology and Data Source
15.1 Methodology
15.2 Research Data Source
15.2.1 Secondary Data
15.2.2 Primary Data
15.2.3 Market Size Estimation
15.3 Legal Disclaimer